Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Karen Christman
Emory University, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ventrix, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Christman is co-founder of Ventrix, Inc. (Ventrix), member of the Board of Directors and Scientific Advisory Board, a consultant earning income in (b)(4) range and has approximately (b)(4) equity interest valued at (b)(4). Ventrix is focused on the development of an injectable hydrogel, VentriGel, which is a biomaterial designed for repair of damaged myocardium in adult cardiac patients. This NIH subaward from Emory University is examining whether a decellularized cardiac extracellular matrix hydrogel can improve cardiac function following right-ventricular failure alone or with cardiac progenitor cells in an effort to gain data for an FDA IND. Dr. Christman will provide oversight related to the hydrogel, rat studies and GLP like documentation.
Injectable Biomaterial for Treating Hypoplastic Left Heart Syndrome
Narrative Congenital heart disease is the most common type of birth defect and few treatments outside of surgical intervention have improved the health and quality of life of these children. We propose to examine whether either a decellularized cardiac extracellular matrix (ECM) can improve cardiac function following right-ventricular failure alone or with cardiac progenitor cells (CPCs) in an effort to gain data for an FDA IND. With both therapies being tested in humans (CPCs in children and cECM in adults), the pathway to translation is direct and studies will yield potential mechanistic insights into repair of the failing RV.
Filed on July 05, 2019.
Tell us what you know about Karen Christman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Karen Christman filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Karen Christman | Emory University | Conflict of Interest | Ventrix, Inc. | $40,000 - $59,999 |
| Karen Christman | University of California, San Diego | Conflict of Interest | Ventrix | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.